Tela Bio, Inc. 8-K Filing
Ticker: TELA · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Tela Bio, Inc. (ticker: TELA) to the SEC on Nov 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market); $45,000 (will receive an annual base retainer of $45,000 for his service on the Board. In accor).
How long is this filing?
Tela Bio, Inc.'s 8-K filing is 3 pages with approximately 950 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 950 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-11-03 16:10:59
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
- $45,000 — will receive an annual base retainer of $45,000 for his service on the Board. In accor
Filing Documents
- tm2530000d1_8k.htm (8-K) — 27KB
- 0001104659-25-105548.txt ( ) — 189KB
- tela-20251031.xsd (EX-101.SCH) — 3KB
- tela-20251031_lab.xml (EX-101.LAB) — 33KB
- tela-20251031_pre.xml (EX-101.PRE) — 22KB
- tm2530000d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2025, the Board of Directors (the " Board ") of TELA Bio, Inc. (the " Company ") increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed William Plovanic to serve as a Class I director, with a term expiring at the Company's 2026 Annual Meeting of Stockholders. Mr. Plovanic, 56, has served as Managing Director, Healthcare Equity Research at Canaccord Genuity LLC (" Canaccord "), a global investment bank focused on growth companies, since May 2020. As Managing Director, Mr. Plovanic leads equity research coverage of medical technology sectors, including cardiovascular, diabetes, and neuromodulation. Previously, Mr. Plovanic served as President, Chief Executive Officer, Chief Financial Officer, and as a board member at Obalon Therapeutics, Inc. (" Obalon ") (formerly, Nasdaq: OBLN), a previously publicly traded medical device company, from March 2016 until a merger with ReShape LifeSciences, Inc. (formerly, Nasdaq: RSLS) in June 2021. At Obalon, Mr. Plovanic guided the company through commercialization of novel obesity treatment technologies and services, significant organizational changes, and its eventual merger with ReShape LifeSciences. Prior to Obalon, Mr. Plovanic worked as an equity research analyst for 20 years covering medical technology companies in the orthopedics and biomaterials sectors. Mr. Plovanic holds a Bachelor of Science in Finance from Bradley University and is a Chartered Financial Analyst (CFA) Charterholder. The Board has determined that Mr. Plovanic is an independent director under the applicable Nasdaq listing rules. There are no arrangements or understandings between Mr. Plovanic and any other person pursuant to which he was selected as a director. There are no relat
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: Chief Executive Officer and Director Date: November 3, 2025